Identification of a kappa-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis

Keyphrases

• Drug Development 100%
• Human African Trypanosomiasis 100%
• U50,488 100%
• Kappa Opioid 100%
• IC50 Value 66%
• Antitrypanosomal Activity 66%
• Resazurin 66%
• Cell Viability Assay 66%
• Divergence 33%
• Tubulin 33%
• Protein Kinase 33%
• T. Brucei 33%
• Trypanosoma Brucei 33%
• Compound Classes 33%
• Novel Inhibitors 33%
• Energy Metabolism 33%
• Human Fibroblasts 33%
• Opioid Receptors 33%
• Antinociceptive 33%
• Pharmacologically Active Compounds 33%
• Phenotypic Screening 33%
• Pharmaceutical Properties 33%
• Brain Penetration 33%
• CNS-active 33%
• Cytostatic Drugs 33%
• Topoisomerase 33%
• LOPAC 33%
• μ-opioid Antagonist 33%
• Pentamidine 33%
• DNA Metabolism 33%
• Suramin 33%
• Bioinformatics Study 33%
• Structurally Related Compounds 33%
• Kappa Opioid Receptor Agonist 33%
• Mouse Infection 33%
• Oral Route 33%
• Selective Screening 33%
• Well Tolerated 33%
• Bloodstream Form 33%

Pharmacology, Toxicology and Pharmaceutical Science

• African Trypanosomiasis 100%
• Drug Development 100%
• 3,4 Dichloro N Methyl N [2 (1 Pyrrolidinyl)cyclohexyl]benzeneacetamide 100%
• Kappa Opiate Receptor Agonist 100%
• Cell Viability 66%
• Antitrypanosomal 66%
• Viability Assay 66%
• Resazurin 66%
• EC50 66%
• Protein Kinases 33%
• Trypanosoma Brucei 33%
• Tubulin 33%
• Infection 33%
• Mouse Model 33%
• Opiate Receptor 33%
• Kappa Antagonists 33%
• Suramin 33%
• Pentamidine 33%
• Mu Opiate Receptor Antagonist 33%
• Cytostatic 33%